Claude Wildmann

TL;DR: The identification of a new gene that codes for a putative protein of 43 aa and seems to belong to a family of several genes, which may prove useful for cancer immunotherapy.

TL;DR: The identification of a gene, named MAGE‐1, which codes for antigen MZ2‐E which is presented by HLA‐A1 is reported and the range of tumor patients who could be eligible for immunization against MAGE antigens is extended.

TL;DR: It is concluded that tum- mutation P198 generates a new epitope recognized by syngeneic T cells that is able to compete for binding to major histocompatibility complex molecule Kd.

TL;DR: The human tyrosinase gene has been reported previously to code for two distinct antigens recognized on HLA‐A2 melanoma cells by autologous cytolytic T lymphocytes by stimulating lymphocytes of melanoma patient MZ2 with a subclone of the tumor cell line of this patient, and a CTL clone was obtained which recognized tumor cells expressing tyrosInase and HLA•B*4402.

TL;DR: It is shown that galectin-3 secreted by tumours binds both glycosylated IFNγ and glycoproteins of the tumour extracellular matrix, thus avoiding IFNνγ diffusion and the formation of anIFNγ-induced chemokine gradient required for T cell infiltration.